Home > Insider Trading > Filing (0000947871-24-000721)

Filing Details

Accession Number:: 0000947871-24-000721
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-08-23 18:41:21
Reporting Period:: 2024-08-21

Accepted Time:: 2024-08-23 18:41:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1671858	Ars Pharmaceuticals Inc.	SPRY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-08-21	394,400	$13.52	557,977	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2024-08-21	13,300	$14.61	544,677	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2024-08-22	391,482	$12.94	153,195	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2024-08-23	69,500	$13.03	83,695	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	269,323	Indirect	See Footnote
Common Stock	8,019,187	Indirect	See Footnote

Footnotes

Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $13.30 to a high of $13.925 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $14.605 to a high of $14.615 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.765 to a high of $13.475 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.80 to a high of $13.20 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC ("OrbiMed Advisors"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM.
These securities are held of record by OPI VI - IP HoldCo LLC ("HoldCo"). OrbiMed Capital GP VI LLC ("GP VI") is the sole member of OrbiMed Private Investments VI - IP, LP, which is the sole member of OPI VI - IP TopCo LLC, the sole member of HoldCo. OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by HoldCo and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by HoldCo.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). GP VI is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.